SIGLEC1 and neoplasm: Using a combination of in vitro assays and in vivo models, this study will investigate the efficacy of virus-like liposomes as novel nano-vaccine carriers that target CD169 antigen presenting cells for cross-presentation and tumor-specific T cell activation—to prolong survival and to contribute to a better quality of life of cancer patients.